

| | |
|-------------------------|--|
| 1. Record Nr. | UNINA9910154921903321 |
| Autore | Yu Helen |
| Titolo | Achieving proof of concept in drug discovery and development : the role of competition law in collaborations between public research organizations and industry / / Helen Yu |
| Pubbl/distr/stampa | Cheltenham, [England] ; ; Northampton, Massachusetts : , : Edward Elgar Publishing, , 2016 ©2016 |
| ISBN | 1-78536-937-7 |
| Descrizione fisica | 1 online resource (280 pages) |
| Disciplina | 346.73048 |
| Soggetti | Intellectual property - United States |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Nota di bibliografia | Includes bibliographical references and index. |
| Nota di contenuto | . Introduction -- The pharmaceutical industry and drug development models -- Intellectual property rights and competition law in collaborative drug development between industry and integrated drug discovery organizations -- Application of competition law to the integrated drug discovery model: research and development block exemption regulation -- Application of competition law to the integrated drug discovery model: technology transfer block exemption regulation -- Analysis of collaboration agreements between integrated drug discovery organizations and industry -- 7. Conclusion and implications. |
| Sommario/riassunto | One of the major shortcomings of the current drug discovery and development process is the inability to bridge the gap between early stage discoveries and pre-clinical research in order to advance innovations beyond the discovery phase. This book examines a drug discovery and development model, where the respective expertise of academia and industry are brought together to take promising discoveries through to proof of concept, providing a means to de-risk the drug discovery and development process. Expert author Helen Yu explores integrated drug discovery by analyzing the intersection of intellectual property law and competition law and discusses the role of stakeholders in the efficient translation and commercialization of |

publically funded research. Considering the transactional risks associated with drug discovery and development, this book advocates for a greater emphasis on contractual freedom and economic efficiency when assessing collaborative partnerships between industry and public research organizations. This standout book bridges the gap between theoretical research and legal practice by providing a research-based applied perspective on university-industry collaborations in drug age 4 of cover. .
